Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Cardiology Research Dubrava registry is a prospective, single centre registry including patients with acute coronary syndrome with and without ST segment elevation, patients with heart failure who were prescribed with SGLT-2 inhibitors, patients implanted with TAVI, patients with venous thromboembolism, patients with pulmonary embolism who underwent thromboaspiration procedure, patients implanted with ICD, CRT and conduction system pacing devices, as well as patients with atrial fibrillation who underwent pulmonary vein isolation and are prescribed with long-term anticoagulation therapy.
Cardiology Research Dubrava registry is a prospective, single centre registry including patients with acute coronary syndrome with and without ST segment elevation, patients with heart failure who were prescribed with SGLT-2 inhibitors, patients implanted with TAVI, patients with venous thromboembolism, patients with pulmonary embolism who underwent thromboaspiration procedure, patients implanted with ICD, CRT and conduction system pacing devices, as well as patients with atrial fibrillation who underwent pulmonary vein isolation and are prescribed with long-term anticoagulation therapy.
In this long-term follow-up registry we plan to collect data on clinical status, standard laboratory results including lipidogram values, NTproBNP values after specific interventions (in.ex. TAVI implantation, SGLT2inh prescripition), bleeding complications, and every major cardiovascular event, including cardiovascular death and all cause death.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Acute coronary syndrome - ACS | patients who were diagnosed with acute coronary syndrome: STEMI, non-STE ACS - NSTEMI and unstable angina, who underwent coronary angiography and were prescribed with optimal medicament therapy |
| |
| Transcatheter aortic valve implantation - TAVI | patients with aortic stenosis who underwent transcatheter percotaneous implantation of the arteficial aortic valve |
| |
| Venous thromboembolism - VTE | patients with pulmonary embolism and deep vein thrombosis, with a focus on those who underwent thromboaspiration due to high or medium-high risk pulmonary embolism |
| |
| Heart failure with SGLT2 inhibitor therapy included - HF-SGLT2 | patients with heart failure with reduced, mid-reduced and preserved systolic function who were prescribed with a SGLT-2 inhibitor therapy, and other optimal medicament therapy for HF |
| |
| Cardiac implantable electronic device - CIED | patients who were implanted with a cardiac implantable electronic device: pacemaker, conduction system pacing device, cardioverter-defibrilator or cardiac resynchronization therapy with or without defibrilator option |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| SGLT-2 inh therapy, CIED implantation, thromboaspiration, | Other | long-term follow up and observation of patients treated in Cardiology department in the tertiary center and University hospital |
| Measure | Description | Time Frame |
|---|---|---|
| cardiovascular death | death due to cardiovascular etiology during long term follow-up | 10 years |
| freedom from atrial arrhythmias | Freedom from atrial arrhythmias after PVI during mid-term folow-up (1 year) and long-term follow-up | 10 years |
| Time to revascularization | Time to revascularization during acute coronary syndrome | 10 years |
| Bleeding complications | Bleeding complications during long-term follow-up in patients prescribed with oral anticoagulation and/or antithrombotic therapy | 10 years |
| Laboratory levels of NTproBNP | Laboratory levels of NTproBNP in patients with AFib after PVI, in patients with HF prescribed with SGLT2 inhibitors, in patients with ACS after complete revasculariazation, in patients implanted with CIED | 10 years |
Not provided
Not provided
Inclusion Criteria: patients implanted with CIED, or with VTE, or with ACS or with TAVI -
Exclusion Criteria: non compliance, not undergoing follow-up at this center
-
Not provided
Not provided
Not provided
patients with different cardiology pathology and diseases including arrhythmias, heart failure, venousn thromboembolism, implanted with CIED
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Ivan Zeljkovic, M.D. | Contact | 00385917823289 | kardio@kbd.hr | |
| Ivana Jurin, M.D. | Contact | ivanajurin1912@gmail.com |
| Name | Affiliation | Role |
|---|---|---|
| Ivana Jurin, M.D. | Dubrava University Hospital | Study Chair |
| Irzal Hadzibegovic, M.D. | Dubrava University Hospital | Principal Investigator |
| Nikola Pavlovic, M.D. |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Dubrava University Hospital | Recruiting | Zagreb | 10000 | Croatia |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 42356030 | Derived | Radic M, Jurin I, Rode F, Simunovic L, Kolundzic P, Hadzibegovic I, Manola S, Vitlov P, Ivanovic Mihajlovic V, Grizelj D, Falak H, Udovicic M, Letilovic T. Heart Failure Etiology and 6-Month Cardiorenal Recovery Patterns After Early In-Hospital SGLT2 Inhibitor Initiation in HFrEF: A Prospective Real-World Cohort. Medicina (Kaunas). 2026 May 24;62(6):1017. doi: 10.3390/medicina62061017. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D006333 | Heart Failure |
| D001145 | Arrhythmias, Cardiac |
| D001281 | Atrial Fibrillation |
| D054058 | Acute Coronary Syndrome |
| ID | Term |
|---|---|
| D006331 | Heart Diseases |
| D002318 | Cardiovascular Diseases |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Arrhythmias | patients who underwent electrophysiology study, including PVI for atrial fibrillation, as well as SVT ablations, and ventricular arrhythmia ablation (both premature ventriclar beats and ventricular tachycardia ablation in ischsmic and non-ischemic cardiomyopathy). |
| Dubrava University Hospital |
| Principal Investigator |
| Marin Pavlov, M.D. | Dubrava University Hospital | Principal Investigator |
| Mario Udovicic, M.D. | Dubrava University Hospital | Principal Investigator |
| Danijel Unic, M.D. | Dubrava University Hospital | Principal Investigator |
| Ana Jordan, M.D. | Dubrava University Hospital | Principal Investigator |
| Tomislav Sipic, M.D. | Dubrava University Hospital | Principal Investigator |
| Diana Rudan, M.D. | Dubrava University Hospital | Principal Investigator |
| Sime Manola, M.D. | Dubrava University Hospital | Study Director |
| D017202 | Myocardial Ischemia |
| D014652 | Vascular Diseases |